Aurobindo Pharma gains on USFDA nod for anesthesia injections
The company has received approval from USFDA to manufacture and market Atracurium Besylate Injections
Shares of Aurobindo Pharma were up over 1% at 1,340 after the company said it has received approval from USFDA to manufacture and market Atracurium Besylate Injection, 10mg/ml, 5 ml single-dose vials and 10 mg/ml, 10ml multi-dose vials.
The said injections are bioequivalent and therapeutically equivalent to the reference listed drug product Atracurium Besylate Injections USP of Eurohealth International Sarl, the company said in a release today.
The injections are indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation, the release added.
The stock opened at Rs 1,330 and touched a high of Rs 1,354. At 13:35, over 1.3 million shares were traded on both the stock exchanges.
The said injections are bioequivalent and therapeutically equivalent to the reference listed drug product Atracurium Besylate Injections USP of Eurohealth International Sarl, the company said in a release today.
The injections are indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation, the release added.
The stock opened at Rs 1,330 and touched a high of Rs 1,354. At 13:35, over 1.3 million shares were traded on both the stock exchanges.
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Apr 09 2015 | 1:35 PM IST